Victoria N. Pyliv

ORCID: 0000-0003-0475-0872
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • PI3K/AKT/mTOR signaling in cancer

York District Hospital
2022

Tatyana N. Sokolova Tatyana I. Solov'eva Svetlana N. Aleksakhina M. B. Bolieva V. Е. Goldberg and 79 more Marianna V. Kibisheva К. V. Menshikov Dmitrii V. Ryazanov Aleksandr V. Shkradyuk Yana Chapko Anna A. Shchukina Idris M. Khabriev Dmitrii V. Kirtbaya Alexey M. Degtyarev Aleksandr A. Epkhiev Yana A. Tyugina Aleksandr V. Togo Mirza A. Murachuev Aglaya G. Ievleva Evgenii N. Imyanitov A. A. Grechkina Alena S. Stel'makh Svetlana V. Odintsova Grigorii A. Janus Khedi S. Musaeva V. L. Chang A. V. Fateeva Ekaterina P. Startseva Н. О. Попова Yulia Vsevolodovna Mikheeva Anna Vasilevskaya Victoria S. Barbara Petimat I. Khabibulaeva Alina Khlobystina Ludmila V. Bembeeva Vladimir I. Vladimirov Oleg L. Petrenko Natalia G. Ruskova Ekaterina L. Serikova Ksenia S. Subbotina Svetlana A. Tkachenko D. Yu. Yukalchuk Elena Basova M Stepanova Sanal P. Erdniev А. Yu. Goryainova M. I. Gluzman Р. В. Орлова Anastasiya I. Stukan Р. А. Зуков Alena V. Zyuzyukina Yulia N. Murunova А. В. Султанбаев Elena N. Vorobeva Leonid M. Mikhaevich Anna N. Lysenko Z. K. Khachmamuk Andrey E. Kozlov S. Yu. Bakharev Victoria N. Pyliv Irina K. Amirkhanova Shahen G. Parsyan Elena I. Rossokha Leri D. Osidze Irina S. Shumskaya A. V. Agaeva Tatiana A. Kasmynina Veronika V. Klimenko Kamila T. Akhmetgareeva A. A. Vakhitova Madina D. Chakhkieva Yana A. Udalova В. Н. Дмитриев Yana I. Bakshun Alexey E. Vasilyev Gasimly Dunya D Nadezhda A. Kravchenko Dmitriy A. Maksimov Alfia I. Nesterova Zaur M. Khamgokov Ineza O. Sharvashidze Christina H. Gadzaova Galina G. Rakhmankulova Kseniya A. Shvaiko

Background. By 2020, breast cancer (BC) has become the most frequent malignancy in world. The common type of BC is HR+/HER2-negative cancer,2540% which harbors PIK3CA mutations that affect catalytic subunit PI3K protein. alterations are actionable, as such neoplasms can be treated with a combination fulvestrant and inhibitor alpelisib. As have an extremely versatile effect on characteristics tumor cell, numerous associations various clinico-pathological traced.
 Aim. Our aim was to...

10.26442/8151434.2022.1.201435 article EN Journal of Modern Oncology 2022-04-30
Coming Soon ...